LORLATINIB

Brand name:

• Lorviqua®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Pfizer Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Locally advanced (stage IIIB) or metastatic (stage IV) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (–)

Comment:

--

Other PBAC consideration:

• LORLATINIB

Submission received for:

December 2021 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 10/12/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

07/01/2022

Lodgement of required documentation:

14/01/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 20/01/2022

Status:

Finalised

Government processes:

Commenced on 10/10/2022

Medicine listed on the PBS:

01/12/2022 (see PBS schedule)